Loading
A phase 2 trial of Rituximab, Methotrexate, Procarbazine, Temozolomide, Lisocabtagene maraleucel and Fludarabine in non-Hodgkin lymphoma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma is a phase 2 interventional study registered as NCT07015242 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 65 participants planned, started 2025-11-06 and due to reach its primary completion in 2028-01-09. Interventions recorded: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel and Fludarabine.
Shares Rituximab, Bristol Myers Squibb, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bristol Myers Squibb, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Fludarabine, Rituximab and the tag pipeline.
Shares Temozolomide, Bristol Myers Squibb and the tag pipeline.
Shares Fludarabine, Rituximab and the tag pipeline.
Shares Temozolomide, Bristol Myers Squibb and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.